1. Discuss the pathogenesis of ILD in systemic sclerosis.
2. Discuss the benefits and harms of nintedanib as a new FDA approved therapeutic option for ILD in systemic sclerosis.
Tuesday, February 4, 2020 - 8:30am to 9:30am
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation